Atmowihardjo, Leila N.
Schippers, Job R.
Duijvelaar, Erik
Bartelink, Imke H.
Bet, Pierre M.
Swart, Noortje E. L.
van Rein, Nienke
Purdy, Keith
Cavalla, David
McElroy, Andrew
Fritchley, Sarah
Vonk Noordegraaf, Anton
Endeman, Henrik
van Velzen, Patricia
Koopmans, Matty
Bogaard, Harm Jan
Heunks, Leo
Juffermans, Nicole
Schultz, Marcus J.
Tuinman, Pieter R.
Bos, Lieuwe D. J.
Aman, Jurjan
Article History
Received: 4 April 2023
Accepted: 31 May 2023
First Online: 8 June 2023
Declarations
:
: The medical ethics review committee of the Amsterdam UMC, location VUMC (reference number 2020.0752, approved on 21 January 2021) approved the InventCOVID trial and written informed consent for the use of clinical data, PiCCO measurements and blood samples was obtained from the patient or their legal representatives. The trial was conducted according to the principles of the World Medical Association’s Declaration of Helsinki.
: Not applicable.
: JA and AVN are inventors of a patent (WO2012150857A1; 2011) covering protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg). JA reports serving as a non-compensated scientific advisor for Exvastat. All other authors declare no competing interests.